Amgen

We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

In the last 7 days

Amgen (AMGN) Advances While Market Declines: Some Information for Investors Zacks18:50 14-Jan-26

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses Benzinga12:44 14-Jan-26

JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data Clinical Trials Arena07:05 14-Jan-26

Ro partners with Amgen to study barriers to obesity care, GLP-1 access Investing.com10:30 13-Jan-26

Ro Announces Research Collaboration To Better Understand And Improve The Real-World Patient… PR Newswire (Press Release)08:06 13-Jan-26

Amgen to announce data on obesity drug MariTide at healthcare conference Yahoo! US18:53 12-Jan-26

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Zacks10:06 12-Jan-26

In the last month

Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know Zacks18:58 8-Jan-26

Amgen Reaches Analyst Target Price Nasdaq06:56 8-Jan-26

Biotech Amgen acquires UK-based Dark Blue Therapeutics in $840m deal Silicon Republic04:34 8-Jan-26

Amgen To Present At The 44TH Annual J.P. Morgan Healthcare Conference PR Newswire (Press Release)16:06 7-Jan-26

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs Benzinga13:48 7-Jan-26

Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline Zacks09:37 7-Jan-26

Amgen buys Dark Blue Therapeutics for up to $840m Business Weekly09:21 7-Jan-26

Dark Blue Therapeutics acquired by Amgen for up to £622m UKTN (UK Tech News)08:10 7-Jan-26

Amgen agrees to lower prescription drug costs in deal with US government PMLiVE07:52 7-Jan-26

Amgen acquires UK cancer biotech Dark Blue Therapeutics for $840m European Pharmaceutical Review07:30 7-Jan-26

Amgen buys Dark Blue Therapeutics in $840m oncology deal Pharmaceutical Technology07:09 7-Jan-26

Nasdaq’s Amgen swoops for Dark Blue Therapeutics in £622m deal BusinessCloud.co.uk06:49 7-Jan-26

Amgen’s Own High Court Loss Cited in Pushback to Evenity Claims Bloomberg Law14:08 6-Jan-26

Amgen buys UK biotech Dark Blue Therapeutics for up to $840m ShareCast11:08 6-Jan-26

Amgen inks $840m takeover of UK's Dark Blue Therapeutics pharmaphorum10:43 6-Jan-26

Dark Blue Therapeutics acquired by Amgen for up to $840 million PR Newswire (Press Release)09:35 6-Jan-26

Amgen Acquires Dark Blue Therapeutics, Bolstering Oncology Pipeline PR Newswire (Press Release)09:05 6-Jan-26

What to Expect From Amgen's Q4 2025 Earnings Report Barchart07:07 6-Jan-26

Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors Zacks19:02 5-Jan-26

Can Amgen's MariTide Take on Leaders in the Obesity Space? Zacks12:06 30-Dec-25

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It Zacks10:04 29-Dec-25

UPC Aligns With the EPO in Allowing Functional Antibody Claims JD Supra13:20 26-Dec-25

Pharmaceutical Policy in Motion Continued: Trump Inks Nine New Drug Pricing Deals JD Supra09:35 26-Dec-25

Does FDA’s UPLIZNA gMG Expansion Reshape the Bull Case for Amgen’s Diversification Story (AMGN)? Simply Wall St22:17 25-Dec-25

Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know Zacks11:36 24-Dec-25

Regeneron Seeks to Bifurcate or Stay Amgen’s Antitrust Claims in Aflibercept Patent Litigation JD Supra13:00 23-Dec-25

Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice? Zacks11:19 23-Dec-25

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know Zacks19:00 22-Dec-25

Fitch upgrades Amgen to ’BBB+’ on improved financial structure Investing.com18:34 22-Dec-25

Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements Simply Wall St14:56 21-Dec-25

Amgen Takes Action With The U.S. Government To Lower The Cost Of Medicines For American Patients Amgen (Press Release)14:33 19-Dec-25

view more headlines

14 Jan 18:50

Amgen

Biotech Top Stories

Business Top Stories